Ascletis Pharma Advances in Phase III Acne Treatment Trial

Ascletis Pharma, Inc. (HK:1672) has released an update.

Ascletis Pharma Inc. has successfully completed the enrollment of 480 patients for its Phase III clinical trial of ASC40, an oral treatment for moderate to severe acne, with results expected by the second quarter of 2025. The trial aims to assess the efficacy and safety of ASC40, a novel inhibitor of fatty acid synthase, which has already shown promising results in a previous Phase II trial. Investors and shareholders are keenly watching as the company progresses with this potential breakthrough in acne treatment.

For further insights into HK:1672 stock, check out TipRanks’ Stock Analysis page.